全文获取类型
收费全文 | 40245篇 |
免费 | 2438篇 |
国内免费 | 46篇 |
专业分类
耳鼻咽喉 | 660篇 |
儿科学 | 1879篇 |
妇产科学 | 994篇 |
基础医学 | 4666篇 |
口腔科学 | 1936篇 |
临床医学 | 3558篇 |
内科学 | 8294篇 |
皮肤病学 | 1092篇 |
神经病学 | 3281篇 |
特种医学 | 1362篇 |
外科学 | 6475篇 |
综合类 | 157篇 |
一般理论 | 17篇 |
预防医学 | 2538篇 |
眼科学 | 1032篇 |
药学 | 2563篇 |
中国医学 | 175篇 |
肿瘤学 | 2050篇 |
出版年
2024年 | 34篇 |
2023年 | 357篇 |
2022年 | 202篇 |
2021年 | 679篇 |
2020年 | 457篇 |
2019年 | 733篇 |
2018年 | 1346篇 |
2017年 | 958篇 |
2016年 | 1025篇 |
2015年 | 917篇 |
2014年 | 1038篇 |
2013年 | 1765篇 |
2012年 | 2912篇 |
2011年 | 3483篇 |
2010年 | 1522篇 |
2009年 | 892篇 |
2008年 | 2912篇 |
2007年 | 3135篇 |
2006年 | 3016篇 |
2005年 | 3015篇 |
2004年 | 2868篇 |
2003年 | 2696篇 |
2002年 | 2540篇 |
2001年 | 844篇 |
2000年 | 978篇 |
1999年 | 548篇 |
1998年 | 232篇 |
1997年 | 203篇 |
1996年 | 176篇 |
1995年 | 149篇 |
1994年 | 121篇 |
1993年 | 109篇 |
1992年 | 81篇 |
1991年 | 60篇 |
1990年 | 69篇 |
1989年 | 58篇 |
1988年 | 52篇 |
1987年 | 41篇 |
1986年 | 38篇 |
1985年 | 53篇 |
1984年 | 48篇 |
1983年 | 37篇 |
1982年 | 53篇 |
1981年 | 44篇 |
1980年 | 41篇 |
1979年 | 28篇 |
1978年 | 26篇 |
1977年 | 33篇 |
1976年 | 17篇 |
1973年 | 14篇 |
排序方式: 共有10000条查询结果,搜索用时 750 毫秒
991.
Cairns RA Iqbal J Lemonnier F Kucuk C de Leval L Jais JP Parrens M Martin A Xerri L Brousset P Chan LC Chan WC Gaulard P Mak TW 《Blood》2012,119(8):1901-1903
Mutations in isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) occur in most grade 2 and 3 gliomas, secondary glioblastomas, and a subset of acute myelogenous leukemias but have not been detected in other tumor types. The mutations occur at specific arginine residues and result in the acquisition of a novel enzymatic activity that converts 2-oxoglutarate to D-2-hydroxyglutarate. This study reports IDH1 and IDH2 genotyping results from a set of lymphomas, which included a large set of peripheral T-cell lymphomas. IDH2 mutations were identified in approximately 20% of angioimmunoblastic T-cell lymphomas (AITLs), but not in other peripheral T-cell lymphoma entities. These results were confirmed in an independent set of AITL patients, where the IDH2 mutation rate was approximately 45%. This is the second common genetic lesion identified in AITL after TET2 and extends the number of neoplastic diseases where IDH1 and IDH2 mutations may play a role. 相似文献
992.
993.
994.
Tai X Van Laethem F Pobezinsky L Guinter T Sharrow SO Adams A Granger L Kruhlak M Lindsten T Thompson CB Feigenbaum L Singer A 《Blood》2012,119(22):5155-5163
CTLA-4 proteins contribute to the suppressor function of regulatory T cells (Tregs), but the mechanism by which they do so remains incompletely understood. In the present study, we assessed CTLA-4 protein function in both Tregs and conventional (Tconv) CD4(+) T cells. We report that CTLA-4 proteins are responsible for all 3 characteristic Treg functions of suppression, TCR hyposignaling, and anergy. However, Treg suppression and anergy only required the external domain of CTLA-4, whereas TCR hyposignaling required its internal domain. Surprisingly, TCR hyposignaling was neither required for Treg suppression nor anergy because costimulatory blockade by the external domain of CTLA-4 was sufficient for both functions. We also report that CTLA-4 proteins were localized in Tregs in submembrane vesicles that rapidly recycled to/from the cell surface, whereas CTLA-4 proteins in naive Tconv cells were retained in Golgi vesicles away from the cell membrane and had no effect on Tconv cell function. However, TCR signaling of Tconv cells released CTLA-4 proteins from Golgi retention and caused activated Tconv cells to acquire suppressor function. Therefore, the results of this study demonstrate the importance of intracellular localization for CTLA-4 protein function and reveal that CTLA-4 protein externalization imparts suppressor function to both regulatory and conventional CD4(+) T cells. 相似文献
995.
996.
997.
VT Garrido R Proença-Ferreira VM Dominical F Traina MA Bezerra MR de Mello MP Colella AS Araújo ST Saad FF Costa N Conran 《British journal of haematology》2012,158(6):788-797
Chronic vascular inflammation and endothelial activation may initiate vaso‐occlusion in sickle cell disease (SCD). TNFSF14 (CD258; LIGHT), a recently‐identified pro‐thrombotic and pro‐inflammatory tumour necrosis factor (TNF)‐superfamily cytokine, has a potent activating effect on endothelial cells. We evaluated whether TNFSF14 production is altered in SCD and whether platelets contribute to this production. TNFSF14 was measured in platelet‐free plasma from healthy‐control individuals (CON), steady‐state sickle cell anaemia (SCA), SCA on hydroxycarbamide therapy (SCAHC) and haemoglobin SC (HbSC) patients. Mean plasma TNFSF14 was significantly increased in SCA, SCAHC and HbSC, compared to CON individuals. In SCA/SCAHC patients, plasma TNFSF14, showed no correlation with haematological variables, but was significantly correlated with serum lactate dehydrogenase and inflammatory markers (CD40LG , IL8 and ICAM1). Platelet‐membrane TNFSF14 expression was significantly augmented on SCA platelets, and correlated with platelet activation; furthermore, measurement of platelet TNFSF14 release indicated that platelets may be a major source of circulating TNFSF14 in SCA. Interestingly, high plasma TNFSF14 was significantly associated with elevated tricuspid regurgitant velocity (≥2·5 m/s) in a population of SCA/SCAHC patients. The pro‐inflammatory and atherogenic cytokine, TNFSF14, could contribute to endothelial activation and inflammation in SCA; future investigations may confirm whether this protein contributes to major clinical complications of the disease, such as pulmonary hypertension, and represents a potential therapeutic target. 相似文献
998.
999.